Global eye care leader Alcon has announced the launch of the Hydrus® Microstent in India, introducing a minimally invasive surgical option designed to help manage intraocular pressure (IOP) in patients with mild to moderate open-angle glaucoma. The device is intended to be implanted during cataract surgery and offers a clinically proven approach to reducing both eye pressure and dependency on glaucoma medications.

The Hydrus Microstent belongs to the category of Minimally Invasive Glaucoma Surgery (MIGS) devices, which are designed to lower eye pressure while reducing the risks typically associated with more invasive glaucoma procedures. According to Alcon, MIGS procedures enable ophthalmologists to manage glaucoma more effectively with fewer complications and faster visual recovery for patients.

One of the distinguishing features of the Hydrus Microstent is its strong clinical evidence base. The device is supported by results from the HORIZON trial, the first and only MIGS study reporting five-year clinical outcomes. The study demonstrated sustained reduction in intraocular pressure and medication use when the device was implanted during cataract surgery. With over 200,000 implants globally, Hydrus has established itself as a reliable option for long-term glaucoma management.

Commenting on the launch, Dr. Ike Ahmed, Research Director at the Kensington Eye Institute and Professor of Ophthalmology and Visual Sciences at the University of Utah’s John A. Moran Eye Center, highlighted the clinical benefits of the device. He noted that patients who received the Hydrus implant during cataract surgery experienced better outcomes compared to those undergoing cataract surgery alone, including sustained control of intraocular pressure and reduced reliance on medications.

Also Read: Yogi Adityanath Inaugurates Kapil Dev-Founded 300-Bed Super-Specialty Hospital in Greater Noida

The introduction of the Hydrus Microstent comes at a crucial time for India’s eye health ecosystem. An estimated 12 million people in the country are affected by glaucoma, with nearly 90 percent of cases remaining undiagnosed, highlighting the urgent need for improved detection and advanced treatment options.

Amar Vyas, Country Head, Alcon India, said the launch reflects the company’s commitment to expanding access to innovative ophthalmic technologies in India. He emphasised that the device’s unique Tri-Modal® mechanism helps restore fluid outflow in the eye by dilating and supporting Schlemm’s canal, thereby enabling effective and long-term pressure control.

With the introduction of Hydrus Microstent, Alcon aims to equip ophthalmic surgeons in India with advanced tools to improve patient outcomes and strengthen glaucoma care across the country.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!